1. |
Inadequate preparedness for pandemic influenza |
|
Inpharma Weekly,
Volume &NA;,
Issue 1420,
2004,
Page 2-2
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
2. |
Therapeutic strategies discussed for infective endocarditis |
|
Inpharma Weekly,
Volume &NA;,
Issue 1420,
2004,
Page 3-3
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
3. |
Rivastigmine leads to clinically relevant QOL improvement |
|
Inpharma Weekly,
Volume &NA;,
Issue 1420,
2004,
Page 4-4
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
4. |
Torasemide outshines furosemide in QOL stakes |
|
Inpharma Weekly,
Volume &NA;,
Issue 1420,
2004,
Page 5-5
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
5. |
ISIS 104838*has shown promising activity in patients with rheumatoid arthritis |
|
Inpharma Weekly,
Volume &NA;,
Issue 1420,
2004,
Page 6-6
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
6. |
Tolvaptan: advantages over standard therapy in CHF |
|
Inpharma Weekly,
Volume &NA;,
Issue 1420,
2004,
Page 7-8
RM Poole,
Preview
|
|
摘要:
The investigational vasopressin V2receptor antagonist tolvaptan [OPC 41061], administered in combination with standard therapy, significantly reduces bodyweight in patients hospitalised for congestive heart failure (CHF), according to results from a placebo-controlled phase II study presented at the 76th Annual Scientific Sessions of the American Heart Association (AHA) [Orlando, US; November 2003]. Furthermore, treatment with tolvaptan reduced all-cause mortality rates at 60 days among patients with severe congestion and those with elevated blood urea nitrogen (BUN) levels. A second study presented at the meeting showed that, unlike furosemide, tolvaptan increased urine production without reducing renal blood flow or glomerular filtration rate or increasing renal vascular resistance.
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
7. |
Dalbavancin*administered once weekly has shown superior efficacy to vancomycin in the treatment of patients with Gram-positive catheter-related bloodstream infections, |
|
Inpharma Weekly,
Volume &NA;,
Issue 1420,
2004,
Page 8-8
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
8. |
Vasopressin superior to epinephrine for asystole after cardiac arrest |
|
Inpharma Weekly,
Volume &NA;,
Issue 1420,
2004,
Page 9-9
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
9. |
IFN-γ-1b: no benefit in idiopathic pulmonary fibrosis |
|
Inpharma Weekly,
Volume &NA;,
Issue 1420,
2004,
Page 10-10
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
10. |
REVERSAL: atorvastatin, not pravastatin, halts plaque growth in CAD |
|
Inpharma Weekly,
Volume &NA;,
Issue 1420,
2004,
Page 11-12
RM Poole,
Preview
|
|
摘要:
The progression of atherosclerosis can be stopped, or even reversed, with a more aggressive lipid-lowering strategy than that recommended by current US treatment guidelines, according to results from a study presented at the 76th Annual Scientific Sessions of the American Heart Association (AHA) [Orlando, US; November 2003]. The REVERSAL study, the first head to head comparison of two statins, showed that intensive treatment with high-dose atorvastatin [Lipitor] prevented further buildup of atherosclerotic plaque in patients with coronary artery disease (CAD). In contrast, less intensive therapy with pravastatin did not halt plaque progression, despite producing a significant reduction from baseline in LDL-cholesterol levels."These results clearly show that aggressively lowering cholesterol levels with atorvastatin calcium stopped the progression of atherosclerosis,"said the principal investigator, Dr Steven Nissen from the Cleveland Clinic Cardiovascular Coordinating Center, Cleveland, US."This study further demonstrates the benefits of aggressively managing cholesterol levels to reduce the risk of atherosclerosis".
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|